Compare Gilead Sciences, Inc. (GILD) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Financial Select Sector SPDR Fund — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while Financial Select Sector SPDR Fund trades at $54.34 (market cap $50.06B). The key difference: Gilead Sciences, Inc. is far larger — about 3.6× Financial Select Sector SPDR Fund's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Financial Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| GILD | XLF | |
|---|---|---|
Market Cap | $182.40B | $50.06B |
Volume | 4,469,821 | 47,464,120 |
Sector | Health | — |
52-Week High | $155.80 | $58.55 |
52-Week Low | $116.74 | $47.80 |
Typical Hold Time | 111 Days | 104 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
XLF trades at $53.75, down 0.48% with bearish technical signals from moving averages. The financial sector faces headwinds as bank stocks lag the S&P 500 by the widest margin since 1990 despite rising profits. Recent Fed stress test changes and interest rate hikes create a mixed environment for financial institutions, with higher rates potentially benefiting some sector components while increasing borrowing costs.
The ETF's concentrated exposure to 76 large-cap financial firms positions it for potential gains from rising rates, though sector underperformance and regulatory uncertainty present near-term challenges. Fund managers increased financial allocations in Q2 2026, suggesting institutional confidence in the sector's rate sensitivity advantages over tech stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
